Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

被引:12
作者
Mallick, Rajiv [1 ]
Solomon, Genevieve [2 ]
Bassett, Paul [3 ]
Zhang, Xiang [1 ]
Patel, Palak [4 ]
Lepeshkina, Oleksandra [5 ]
机构
[1] CSL Behring, King Of Prussia, PA USA
[2] Assoc Patients Immunodeficients Quebec, Quebec City, PQ, Canada
[3] Meridian HealthComms Ltd, Manchester, England
[4] CSL Behring, King Of Prussia, PA USA
[5] Ctr Hosp Univ Laval, Quebec City, PQ, Canada
关键词
Immunodeficiency; Infusion method; Intravenous immunoglobulin (IVIg); Subcutaneous immunoglobulin (SCIg); Patient-reported outcomes; Treatment satisfaction questionnaire for medication 9 (TSQM-9); General health perception (GHP); Patient-reported outcomes measurement information system (PROMIS); Patient acceptable symptom state (PASS); QUALITY-OF-LIFE; IGG SELF-INFUSIONS; RAPID PUSH; CHILDREN; HEALTH; ADULTS; MANAGEMENT; DISEASES;
D O I
10.1186/s13223-022-00746-3
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Understanding the impact of different immunoglobulin (Ig) infusion methods (intravenous [IVIg] and subcutaneous [SCIg]) upon treatment experience can potentially facilitate optimization of patient outcomes. Here, the perspective of patients with primary and secondary immunodeficiency diseases (PID and SID, respectively) receiving IVIg and SCIg was evaluated, in terms of treatment satisfaction, accounting for treatment history, using Association des Patients Immunodeficients du Quebec (APIQ) survey data. Methods: The online APIQ survey (shared October 2020-March 2021) of patients with immunodeficiencies in Canada contained 101 questions on: Ig use, history, and detailed infusion characteristics; as well as structured patient-reported outcomes such as treatment satisfaction (via TSQM-9), symptom state (via PASS), general health perception (via GHP), and physical and mental function (via PROMIS). Adult respondents (& GE; 18 years old) currently using Ig were compared by their current Ig infusion method (IVIg or SCIg cohort) overall, and in a sub-analysis, the IVIg cohort was compared with the SCIg cohort after stratification by respondents who started SCIg when naive to Ig ('SCIg naive') or with previous IVIg experience ('SCIg switch'). Results: In total, 54 respondents currently used IVIg and 242 used SCIg. The average duration per infusion of a weekly SCIg infusion was significantly shorter compared with the average duration of a 3-4 weekly IVIg infusion (p < 0.001). The SCIg cohort was associated with significantly higher scores for the TSQM-9 effectiveness domain compared with the IVIg cohort. The scores for TSQM-9 convenience and global satisfaction domains were similar in the two cohorts. The SCIg cohort was also associated with a significantly higher proportion of respondents who were in an acceptable symptom state and a lower proportion who reported very poor or poor perception of health compared with the IVIg cohort. Further, the SCIg naive subgroup was associated with significantly higher TSQM-9 effectiveness and convenience domain scores compared with the IVIg cohort, while there was no significant difference between the SCIg switch subgroup and the IVIg cohort in terms of convenience. Conclusions: A better understanding of how different IgRT administration methods impact treatment experience and satisfaction may assist with informed treatment decision making and ultimately further improvements in patient outcomes.
引用
收藏
页数:20
相关论文
共 52 条
[21]  
Jimmy Beena, 2011, Oman Med J, V26, P155, DOI 10.5001/omj.2011.38
[22]   Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group [J].
Jolles, S. ;
Sanchez-Ramon, S. ;
Quinti, I. ;
Soler-Palacin, P. ;
Agostini, C. ;
Florkin, B. ;
Couderc, L. -J. ;
Brodszki, N. ;
Jones, A. ;
Longhurst, H. ;
Warnatz, K. ;
Haerynck, F. ;
Matucci, A. ;
de Vries, E. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2017, 190 (02) :226-234
[23]   Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease [J].
Jolles, S. ;
Orange, J. S. ;
Gardulf, A. ;
Stein, M. R. ;
Shapiro, R. ;
Borte, M. ;
Berger, M. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 179 (02) :146-160
[24]   Patients' attitude to subcutaneous immunoglobulin substitution as home therapy [J].
Kittner, J. M. ;
Grimbacher, B. ;
Wulff, W. ;
Jaeger, B. ;
Schmidt, R. E. .
JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (04) :400-405
[25]   Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy [J].
Koterba, Alan P. ;
Stein, Mark R. .
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2014, 10
[26]  
Liu ZAE, 2005, EFFECTIVENESS COST E
[27]   Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years [J].
Lucas, Mary ;
Lee, Martin ;
Lortan, Jenny ;
Lopez-Granados, Eduardo ;
Misbah, Siraj ;
Chapel, Helen .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (06) :1354-1360
[28]   Thresholds of Patient-Reported Outcomes That Define the Patient Acceptable Symptom State in Ankylosing Spondylitis Vary Over Time and by Treatment and Patient Characteristics [J].
Maksymowych, Walter P. ;
Gooch, Katherine ;
Dougados, Maxime ;
Wong, Robert L. ;
Chen, Naijun ;
Kupper, Hartmut ;
Van der Heijde, Desiree .
ARTHRITIS CARE & RESEARCH, 2010, 62 (06) :826-834
[29]   Subcutaneous immunoglobulin in primary immunodeficiency - impact of training and infusion characteristics on patient-reported outcomes [J].
Mallick, R. ;
Henderson, T. ;
Lahue, B. J. ;
Kafal, A. ;
Bassett, P. ;
Scalchunes, C. .
BMC IMMUNOLOGY, 2020, 21 (01)
[30]   Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies [J].
Mallick, Rajiv ;
Jolles, Stephen ;
Kanegane, Hirokazu ;
Agbor-Tarh, Dominique ;
Rojavin, Mikhail .
JOURNAL OF CLINICAL IMMUNOLOGY, 2018, 38 (08) :886-897